Bifidobacterium breve ： Irritable Bowel Syndrome (IBS)
D 研究 予備的な研究（実験室研究、症例報告）のみが存在します。Limited data from small studies. Preliminary evidence for symptom improvement.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
結論
Limited data from small studies. Preliminary evidence for symptom improvement.
Key Study Findings
Review
Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: None
Other
n=1098
8 weeks
Open-label
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …
Dose: None
vs: None (single-arm open-label)
Outcome: Treatment success for abdominal pain and bloating
効果: 73% pain, 81.9% bloating success at T1
<0.001
対象集団: IBS patients from 52 Italian gastroenterologists
Randomized Controlled Trial
n=61
8 weeks
Double-blind
Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …
Dose: None
vs: Placebo
Outcome: IBS-SSS symptom severity score change
効果: None
None
対象集団: Patients with moderate-severe diarrhea-predominant IBS
Randomized Controlled Trial
4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g
vs: Placebo
Outcome: Constipation symptoms
効果: None
P = 0.005
対象集団: IBS patients
Review
Postbiotics: A new member in the biotics family.
Dose: None
vs: None
Outcome: Clinical applications overview
効果: None
None
対象集団: General population (review)
In Vitro
Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …
Dose: None
vs: None
Outcome: Colitis severity
効果: None
None
対象集団: Crohn's disease patients
Key Statistics
2
研究数
150
参加者数
↑
Positive
D
グレード
Referenced Papers
Microbiome research reports
2025
16 件の引用
Beneficial microbes
2025
Frontiers in nutrition
2025
The Yale journal …
2024
5 件の引用
Journal of neurogastroenterology …
2024
4 件の引用
Archivos argentinos de …
2024
3 件の引用
Cureus
2024
1 件の引用
Journal of translational …
2023
30 件の引用
Nutrients
2023
19 件の引用
Journal of neurogastroenterology …
2022
21 件の引用
Journal of microbiology …
2022
15 件の引用
Scientific reports
2022
14 件の引用
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 件の引用
Journal of clinical …
2015
62 件の引用
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 件の引用
Journal of clinical …
2012
207 件の引用
PloS one
2012
31 件の引用
Beneficial microbes
2011
89 件の引用
The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat.
Other
Neurogastroenterology and motility
2010
213 件の引用
BMC gastroenterology
2010
91 件の引用
Alimentary pharmacology & …
2007
102 件の引用
Asia Pacific journal …
2006
Alimentary pharmacology & …
2005
398 件の引用
Journal of clinical …
2004
205 件の引用
Research in microbiology
2001
201 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 1-10 billion CFU/day
- adultgisupport:
- 5-10 billion CFU/day
- neonatalsupport:
- 1-5 billion CFU/day (as directed by pediatrician)
上限量： Well-tolerated up to 10 billion CFU/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | 8 weeks | Positive | 1098 |
| None | 8 weeks | Neutral | 61 |
| 2 g | 4 weeks | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| Serum-derived bovine immunoglobulin (SBI) | -- | Positive | -- |
| None | -- | Positive | -- |
推奨摂取タイミング： Before meals or on empty stomach; for infants, mix with breast milk or formula
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools in infants (transient)
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
既知の相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (use with caution in immunocompromised patients)
耐容上限摂取量： Well-tolerated up to 10 billion CFU/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium breve?
Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Irritable Bowel Syndrome (IBS)
References
- [1] Fabiana Bocchio et al.. Microbiome Res Rep. 2025. Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases. doi:10.20517/mrr.2024.52 PubMed
- [2] L Drago et al.. Benef Microbes. 2025. A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults. doi:10.1163/18762891-bja00097 PubMed
- [3] Ida Marie Bruun Grønbæk et al.. Front Nutr. 2025. Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results … doi:10.3389/fnut.2025.1701341 PubMed
- [4] Mattia Tinazzi et al.. Yale J Biol Med. 2024. Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro … doi:10.59249/JOMF5336 PubMed
- [5] Young Hoon Chang et al.. J Neurogastroenterol Motil. 2024. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. doi:10.5056/jnm23036 PubMed
- [6] María Del C Toca et al.. Arch Argent Pediatr. 2024. Postbiotics: A new member in the biotics family. doi:10.5546/aap.2023-10168.eng PubMed
- [7] Sabine Hazan et al.. Cureus. 2024. Gut Microbiome Alterations Following Oral Serum-Derived Bovine Immunoglobulin Administration in the Management of Dysbiosis. doi:10.7759/cureus.75884 PubMed
- [8] Han Chen et al.. J Transl Med. 2023. Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data. doi:10.1186/s12967-023-03953-7 PubMed
- [9] Xinqi Chen et al.. Nutrients. 2023. Dose-Response Efficacy and Mechanisms of Orally Administered Bifidobacterium breve CCFM683 on IMQ-Induced Psoriasis in Mice. doi:10.3390/nu15081952 PubMed
- [10] Seung Yong Shin et al.. J Neurogastroenterol Motil. 2022. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … doi:10.5056/jnm21202 PubMed
- [11] Yae Jin Choi et al.. J Microbiol Biotechnol. 2022. Immunomodulatory Effects of Bifidobacterium spp. and Use of Bifidobacterium breve and Bifidobacterium longum on Acute Diarrhea in Children. doi:10.4014/jmb.2206.06023 PubMed
- [12] Edgar Torres-Maravilla et al.. Sci Rep. 2022. Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome. doi:10.1038/s41598-022-21746-8 PubMed
- [13] Carrie A M Wegh et al.. J Clin Gastroenterol. 2018. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. doi:10.1097/MCG.0000000000001054 PubMed
- [14] Hyuk Yoon et al.. J Clin Biochem Nutr. 2015. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a … doi:10.3164/jcbn.15-14 PubMed
- [15] María Ortiz-Lucas et al.. Rev Esp Enferm Dig. 2013. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. doi:10.4321/s1130-01082013000100005 PubMed
- [16] Bong Ki Cha et al.. J Clin Gastroenterol. 2012. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … doi:10.1097/MCG.0b013e31823712b1 PubMed
- [17] Eoin Barrett et al.. PLoS One. 2012. Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel … doi:10.1371/journal.pone.0048159 PubMed
- [18] E O'Sullivan et al.. Benef Microbes. 2011. BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels? doi:10.3920/BM2011.0015 PubMed
- [19] D P McKernan et al.. Neurogastroenterol Motil. 2010. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. doi:10.1111/j.1365-2982.2010.01520.x PubMed
- [20] Anna Lyra et al.. BMC Gastroenterol. 2010. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. doi:10.1186/1471-230X-10-110 PubMed
- [21] K Kajander et al.. Aliment Pharmacol Ther. 2007. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. doi:10.1111/j.1365-2036.2007.03391.x PubMed
- [22] Kajsa Kajander et al.. Asia Pac J Clin Nutr. 2006. Clinical studies on alleviating the symptoms of irritable bowel syndrome. PubMed
- [23] K Kajander et al.. Aliment Pharmacol Ther. 2005. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. doi:10.1111/j.1365-2036.2005.02579.x PubMed
- [24] Alfredo Saggioro. J Clin Gastroenterol. 2004. Probiotics in the treatment of irritable bowel syndrome. doi:10.1097/01.mcg.0000129271.98814.e2 PubMed
- [25] P Brigidi et al.. Res Microbiol. 2001. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome … doi:10.1016/s0923-2508(01)01254-2 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。